Abstract:The wild-type SARS-CoV-2 has continuously evolved into several variants with increased transmissibility and virulence. The Delta variant which was initially identified in India created a devastating impact throughout the country during the second wave. While the efficacy of the existing vaccines against the latest SARS-CoV-2 variants remains unclear, extensive research is being carried out to develop potential antiviral drugs through approaches like in silico screening and drug-repurposing. This study aimed to conduct the docking-based virtual screening of 50 potential phytochemical compounds against a Spike glycoprotein of the wild-type and the Delta SARS-CoV-2 variant. Subsequently, molecular docking was performed for the five best compounds, such as Lupeol, Betulin, Hypericin, Corilagin, and Geraniin, along with synthetic controls. From the results obtained, it was evident that Lupeol exhibited a remarkable binding affinity towards the wild-type Spike protein (-8.54 kcal/mol), while Betulin showed significant binding interactions with the mutated Spike protein (-8.83 kcal/mol), respectively. The binding energy values of the selected plant compounds were slightly higher than that of the controls. Key hydrogen bonding and hydrophobic interactions of the resulting complexes were visualized, which explained their greater binding affinity against the target proteins-the Delta S protein of SARS-CoV-2, in particular. The lower RMSD, the RMSF values of the complexes and the ligands, Rg, H-bonds, and the binding free energies of the complexes together revealed the stability of the complexes and significant binding affinities of the ligands towards the target proteins. Our study suggests that Lupeol and Betulin could be considered as potential ligands for SARS-CoV-2 spike antagonists. Further experimental validations might provide new insights for the possible antiviral therapeutic interventions of the identified lead compounds and their analogs against COVID-19 infection.

Teicoplanin derivatives block spike protein mediated viral entry as pan-SARS-CoV-2 inhibitors

Computational View Toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease.

Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Discovery of Novel Spike Inhibitors against SARS-CoV-2 Infection

Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay

Potential Inhibitors for Targeting Mpro and Spike of SARS-CoV-2 Based on Sequence and Structural Pharmacology Analysis

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein

Screening for inhibitors against SARS-CoV-2 and its variants

A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor

Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein

Plant-Derived Antiviral Compounds as Potential Entry Inhibitors against Spike Protein of SARS-CoV-2 Wild-Type and Delta Variant: An Integrative in SilicoApproach

An angiotensin-converting enzyme-2-derived heptapeptide GK-7 for SARS-CoV-2 spike blockade

Ligand- and Structure-Based Virtual Screening Identifies New Inhibitors of the Interaction of the SARS-CoV-2 Spike Protein with the ACE2 Host Receptor

Identification of potent small molecule inhibitors of SARS-CoV-2 entry

Broad-Spectrum Coronavirus Inhibitors Discovered by Modeling Viral Fusion Dynamics

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

Identification of hACE2-interacting sites in SARS-CoV-2 spike receptor binding domain for antiviral drugs screening

Engineered Trimeric ACE2 Binds Viral Spike Protein and Locks It in “Three-Up” Conformation to Potently Inhibit SARS-CoV-2 Infection

Targeting Receptor Binding Domain and Cryptic Pocket of Spike glycoprotein from SARS-CoV-2 by biomolecular modeling

The Study of Antiviral Drugs Targeting SARS-CoV-2 Nucleocapsid and Spike Proteins Through Large-Scale Compound Repurposing.